Combined immunomodulatory therapy proves more effective than other treatments for advanced cutaneous T-cell lymphoma.
Investigators from the Department of Dermatology and the General Clinical Research Center of the Hospital of the University of Pennsylvania in Philadelphia, Pennsylvania, United States, studied 47 patients with a clinical and laboratory diagnosis of cutaneous T-cell lymphoma. Sixty-eight percent of the patients had stage III or stage IV disease.
Circulating malignant T-cells were present in 89 percent of the patients. Six cycles of photophoresis were administered to all of the patients, and 31 also received one or more immunostimulatory agents for three or more months.
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!